At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Habte Yimer of Texas Oncology sat down with Oncology Data Advisor to elaborate on the promising results of brentuximab vedotin for patients with advanced-stage classical Hodgkin lymphoma, including the most recent data and future directions for the trial.
At the recent American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor met with Dr. Hun Lee of MD Anderson to discuss the two abstracts that he presented there. Dr. Lee provided an update on the promising data for zilovertamab plus ibrutinib for patients with mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL), and for brentuximab vedotin plus nivolumab and chemotherapy for patients with Hodgkin lymphoma.
The FDA has expanded the approval of brentuximab vedotin (Adcetris®, Seattle Genetics, Inc.) in combination with chemotherapy as a first-line treatment for adults with systemic anaplastic large cell lymphoma (ALCL) and other peripheral T-cell lymphomas (PTCLs) expressing the tumor marker CD30. This is the first FDA-approved treatment for patients with newly diagnosed PTCLs. Peripheral T-cell lymphomas are a diverse group of rare non-Hodgkin lymphomas that result when the immune system's T cells ...